In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Conor: An Outsider Delivers Drug-Stents' Next Generation

Executive Summary

Drug-eluting stents (DES), now approved in the US, will be the first blockbuster combination drug/device product to hit the market. First generation DES products use a stent design that remains basically unchanged from bare metal stents, bascially adding thin layers of drug and polymer coatings. Conor Medsystems is developing a stent that is specifically designed as a drug delivery vehicle, while still embodying the attributes required of a standard stent. Conor's stent is based on work done by an engineer with no expereince in the medical products industry, based on technology developed in other areas, bringing a fresh look to the future of combining drugs and stents that may extend to therapeutic applications beyond treating only cardiovascular disease.
Advertisement

Related Content

Device Financings: Recent Growth, Future Opportunities
Xtent and the Next DES Boom
From Academia to Commercial Success: An Interview with Frank Litvack, MD
COURAGE Trial: Bad News Again for Stents at ACC, Or Is It?
World Congress of Cardiology: DES Safety Dominates Discussions
Renewed DES Safety Debate Creates Second Generation Mover Advantage
Biotronik's Disappearing Act
PCR's Pas de Deux
At TCT, A New Vision of the Device Industry
Drug Stents: J&J Innovates, Others Stumble

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002122

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel